EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseLeitlinie

The efficacy of immunotherapies for pregnancy outcomes of patients with recurrent implantation failure as defined by ESHRE guidelines: A systematic review and network meta-analysis

Ying Li, Peixuan Lan, Jing Tang, Wenjun Wang, Hui Chen

Journal of Reproductive Immunology · 2026

DOI: 10.1016/j.jri.2025.104825 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Reproductive Immunology, 2026. Verfasst von Ying Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Medicine Center, Department of Obstetrics and Gynecology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yanjiang Xi Road, G…. Hauptthemen laut MEDLINE: Embryo Implantation, Immunotherapy, Abortion, Habitual. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Beijing Health Promotion Association, Natural Science Foundation of Guangdong Province, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the efficacy of immunotherapies for recurrent implantation failure (RIF), as newly defined by ESHRE 2023. We conducted network meta-analyses of randomized trials on immunomodulatory therapies for well-defined RIF from PubMed, Embase, Web of Science, and Cochrane Library up to October 2024. We assessed clinical outcomes, including clinical pregnancy rate (CPR), live birth rate (LBR), implantation rate (IR), and miscarriage rate (MR), using odds ratios (OR) and 95 % confidence-intervals (CI). Statistical analysis was performed with STATA. Nineteen trials involving 2434 women were included, comparing nine immunotherapies. Compared to controls, low-molecular-weight heparin (LMWH) (OR 4.05, 95 %CI 1.78-9.24, surface under the cumulative ranking curve (SUCRA) 77.1 %) and platelet-rich plasma (PRP) (OR 3.27, 95 %CI 1.42-7.52, SUCRA 66.5 %) significantly improve IR, while sirolimus (OR 3.95, 95 %CI 1.46-10.71, SUCRA 81.9 %) and PRP (OR 3.45, 95 %CI 2.45-4.85, SUCRA 80.3 %) notably increased CPR. Subcutaneous granulocyte colony-stimulating factor (SC-GCSF) (OR 9.00, 95 %CI 1.42-57.12, SUCRA 93.7 %) were associated with higher LBR. LMWH (OR 0.12, 95 %CI 0.02-0.80, SUCRA 84.6 %) and PRP reduced MR (OR 0.15, 95 %CI 0.04-0.50, SUCRA 82.2 %). Subgroup analysis indicated that a 0.5 ml intrauterine PRP dose 48 h before embryo transfer (ET) enhanced CPR (OR 3.96, 95 %CI 2.74-5.74) and reduced MR (OR 0.10, 95 %CI 0.04-0.22). In newly defined RIF patients, sirolimus and PRP effectively enhance CPR, while SC-GCSF optimizes LBR. LMWH is most effective for improving IR and reducing MR. PRP, particularly with a single 0.5 ml intrauterine dose, optimally increases CPR and reduces MR. Intrauterine G-CSF showed no significant benefits. TRIAL REGISTRATION: The protocol was registered on OSF: https://doi.org/10.17605/OSF.IO/GVEP9.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Embryo ImplantationImmunotherapyAbortion, HabitualHumansFemalePregnancyPregnancy OutcomeHeparin, Low-Molecular-WeightPregnancy RateSirolimusPlatelet-Rich PlasmaEmbryo Transfer

Stichwörter der Autor:innen

ImmunotherapyLow-molecularweight heparinPatelet-rich plasmaRecurrent implantation failureSirolimus

Substanzen

Heparin, Low-Molecular-WeightSirolimus

Autor:innen und Institutionen

  • Reproductive Medicine Center, Department of Obstetrics and Gynecology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yanjiang Xi Road, Guangzhou, Guangdong 510120, China; The First Affiliated Hospital of Sh…
  • Reproductive Medicine Center, Department of Obstetrics and Gynecology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yanjiang Xi Road, Guangzhou, Guangdong 510120, China; Guangdong Provincial Clinical Resea…

Förderung

  • Beijing Health Promotion Association
  • Natural Science Foundation of Guangdong Province
  • National Key Research and Development Program of China
  • High-level Hospital Construction Project of Guangdong Provincial People's Hospital

Zitieren

APA

Li, Y., Lan, P., Tang, J., Wang, W., & Chen, H. (2026). The efficacy of immunotherapies for pregnancy outcomes of patients with recurrent implantation failure as defined by ESHRE guidelines: A systematic review and network meta-analysis. Journal of Reproductive Immunology. https://doi.org/10.1016/j.jri.2025.104825

Vancouver

Li Y, Lan P, Tang J, Wang W, Chen H. The efficacy of immunotherapies for pregnancy outcomes of patients with recurrent implantation failure as defined by ESHRE guidelines: A systematic review and network meta-analysis. Journal of Reproductive Immunology. 2026. doi:10.1016/j.jri.2025.104825

BibTeX
@article{Li2026,
  author = {Li, Ying and Lan, Peixuan and Tang, Jing and Wang, Wenjun and Chen, Hui},
  title = {The efficacy of immunotherapies for pregnancy outcomes of patients with recurrent implantation failure as defined by ESHRE guidelines: A systematic review and network meta-analysis},
  journal = {Journal of Reproductive Immunology},
  year = {2026},
  doi = {10.1016/j.jri.2025.104825}
}
Kostenlos starten →